Literature DB >> 17145791

Aspirin antagonism in isoniazid treatment of tuberculosis in mice.

Sean T Byrne1, Steven M Denkin, Ying Zhang.   

Abstract

Salicylate has previously been shown to reduce the susceptibility of Mycobacterium tuberculosis to several drugs in vitro. In this study, aspirin, a salicylate anti-inflammatory, antagonized isoniazid treatment of murine pulmonary tuberculosis, whereas the nonsalicylate ibuprofen did not. These results may have implications on concurrent administration of anti-inflammatory and antituberculosis drugs.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17145791      PMCID： PMC1797778          DOI： 10.1128/AAC.01145-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

Review 1.  The effects of salicylate on bacteria.

Authors:  C T Price; I R Lee; J E Gustafson
Journal:  Int J Biochem Cell Biol       Date:  2000-10       Impact factor: 5.085

2.  Gene expression profiling analysis of Mycobacterium tuberculosis genes in response to salicylate.

Authors:  Steven Denkin; Sean Byrne; Charles Jie; Ying Zhang
Journal:  Arch Microbiol       Date:  2005-11-10       Impact factor: 2.552

3.  Salicylate reduces susceptibility of Mycobacterium tuberculosis to multiple antituberculosis drugs.

Authors:  Alain Schaller; Zhonghe Sun; Yongping Yang; Akos Somoskovi; Ying Zhang
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

4.  An update on aspirin in the primary prevention of cardiovascular disease.

Authors:  Rachel S Eidelman; Patricia R Hebert; Steven M Weisman; Charles H Hennekens
Journal:  Arch Intern Med       Date:  2003-09-22

5.  Nonheritable resistance to chloramphenicol and other antibiotics induced by salicylates and other chemotactic repellents in Escherichia coli K-12.

Authors:  J L Rosner
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

6.  Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.

Authors:  Eric L Nuermberger; Tetsuyuki Yoshimatsu; Sandeep Tyagi; Richard J O'Brien; Andrew N Vernon; Richard E Chaisson; William R Bishai; Jacques H Grosset
Journal:  Am J Respir Crit Care Med       Date:  2003-10-24       Impact factor: 21.405

7.  inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis.

Authors:  A Banerjee; E Dubnau; A Quemard; V Balasubramanian; K S Um; T Wilson; D Collins; G de Lisle; W R Jacobs
Journal:  Science       Date:  1994-01-14       Impact factor: 47.728

8.  The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis.

Authors:  Y Zhang; B Heym; B Allen; D Young; S Cole
Journal:  Nature       Date:  1992-08-13       Impact factor: 49.962
  8 in total
  13 in total

Review 1.  Host-directed therapeutics for tuberculosis: can we harness the host?

Authors:  Thomas R Hawn; Alastair I Matheson; Stephen N Maley; Omar Vandal
Journal:  Microbiol Mol Biol Rev       Date:  2013-12       Impact factor: 11.056

Review 2.  New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics.

Authors:  Thomas R Hawn; Javeed A Shah; Daniel Kalman
Journal:  Immunol Rev       Date:  2015-03       Impact factor: 12.988

3.  Thrombocyte Inhibition Restores Protective Immunity to Mycobacterial Infection in Zebrafish.

Authors:  Elinor Hortle; Khelsey E Johnson; Matt D Johansen; Tuong Nguyen; Jordan A Shavit; Warwick J Britton; David M Tobin; Stefan H Oehlers
Journal:  J Infect Dis       Date:  2019-07-02       Impact factor: 5.226

Review 4.  Repurposing drugs for treatment of tuberculosis: a role for non-steroidal anti-inflammatory drugs.

Authors:  Arundhati Maitra; Sadé Bates; Monisha Shaik; Dimitrios Evangelopoulos; Ibrahim Abubakar; Timothy D McHugh; Marc Lipman; Sanjib Bhakta
Journal:  Br Med Bull       Date:  2016-05-05       Impact factor: 4.291

Review 5.  Non-Steroidal Anti-inflammatory Drugs As Host-Directed Therapy for Tuberculosis: A Systematic Review.

Authors:  Vera M Kroesen; Matthias I Gröschel; Neil Martinson; Alimuddin Zumla; Markus Maeurer; Tjip S van der Werf; Cristina Vilaplana
Journal:  Front Immunol       Date:  2017-06-30       Impact factor: 7.561

6.  A pilot study to determine the occurrence of concomitant diseases and drug intake in patients on antituberculosis therapy.

Authors:  Ratinder Jhaj; Shweta Sharma; Mohammed Sabir; Arun Kokane
Journal:  J Family Med Prim Care       Date:  2018 Mar-Apr

7.  Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate Mycobacterium tuberculosis infection in aerosol-challenged mice.

Authors:  Rasmus Mortensen; Helena Strand Clemmensen; Joshua S Woodworth; Marie Louise Therkelsen; Tehmina Mustafa; Kristian Tonby; Synne Jenum; Else Marie Agger; Anne Ma Dyrhol-Riise; Peter Andersen
Journal:  Commun Biol       Date:  2019-08-05

Review 8.  Platelet Activation and the Immune Response to Tuberculosis.

Authors:  Daniela E Kirwan; Deborah L W Chong; Jon S Friedland
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

9.  A Beneficial Effect of Low-Dose Aspirin in a Murine Model of Active Tuberculosis.

Authors:  Vera Marie Kroesen; Paula Rodríguez-Martínez; Eric García; Yaiza Rosales; Jorge Díaz; Montse Martín-Céspedes; Gustavo Tapia; Maria Rosa Sarrias; Pere-Joan Cardona; Cristina Vilaplana
Journal:  Front Immunol       Date:  2018-04-23       Impact factor: 7.561

Review 10.  Translational Potential of Therapeutics Targeting Regulatory Myeloid Cells in Tuberculosis.

Authors:  Nelita du Plessis; Leigh A Kotze; Vinzeigh Leukes; Gerhard Walzl
Journal:  Front Cell Infect Microbiol       Date:  2018-09-21       Impact factor: 5.293
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.